Lexeo Therapeutics

LXEONasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$377.689 M

$4.81 +5.71%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$100.0M

Loss-making

Shares outstanding

74,087,063

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#79Fennec PharmaceuticalsFENC$403.8M
#80Compass TherapeuticsCMPX$387.2M
#81Lexeo TherapeuticsLXEO$377.7M
#82Palisade BioPALI$366.3M
#83Century TherapeuticsIPSC$360.7M

Where these numbers come from

Share counts and financials for Lexeo Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.